Evidence map›Paper›PMID 38745670›Full record

ArticleFrontiers in immunology2024

Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.

Ying Jiang, Dan Feng, Jun Zhu, Daolin Wei, Chuxian Zhao, Huixia Liu, Shan Shao, Chun Wang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying JiangDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Dan FengDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Jun ZhuDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Daolin WeiDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Chuxian ZhaoDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Huixia LiuDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Shan ShaoDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
Chun WangDepartment of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials. However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT). We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient's complete remission has persisted for 20 months after HSCT.

Indexed as

Antigens, CD7Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveReceptors, Chimeric AntigenTransplantation, HomologousAdultHumansMalePrecursor T-Cell Lymphoblastic Leukemia-LymphomaTissue DonorsT-LymphocytesTreatment OutcomeAntigens, CD7Receptors, Chimeric AntigenCD7 CAR-Tcomplete remissionHSCTpreventive infusionT-ALL/LBL

Identifiers

PMID38745670
PMCPMC11091287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.